| Summary: | Niroj Kumar Sahoo,1 Richa Ranjan,2 Mudit Tyagi,3 Hitesh Agrawal,3 Subhakar Reddy3 1Department of Retina and Vitreous, L V Prasad Eye Institute, Vijayawada, India; 2Bharti Eye Foundation and Hospital, New Delhi, India; 3Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, IndiaCorrespondence: Mudit TyagiSmt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Banjara Hills, Hyderabad, 34, IndiaTel +91-9553339042Email drmudittyagi@gmail.comAbstract: A gradual shift in trend from primary enucleation to globe salvaging radiation therapy for the management of ocular tumors has resulted in the rise of several post-treatment ocular complications including radiation retinopathy. Radiation retinopathy is a chronic, progressive, and occlusive vasculopathy that can manifest anytime between 1 month to 15 years after starting radiation therapy. The aim of treatment in most of these cases is to prevent further vision loss. Treatment options such as laser photocoagulation, anti-vascular endothelial growth factor and intraviral steroids have been described. However, despite several advances in diagnostic and therapeutic modalities, a significant proportion of eyes with radiation retinopathy eventually go blind. This review summarises some of the clinical features, investigative modalities, and recent therapeutic strategies used in the management of radiation retinopathy.Keywords: radiation retinopathy, radiation maculopathy, anti-VEGFs, laser photocoagulation, ocular tumors
|
|---|
